Skip Navigation


NDT Advance Access originally published online on June 9, 2009
Nephrology Dialysis Transplantation 2009 24(9):2938-2940; doi:10.1093/ndt/gfp278
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/9/2938    most recent
gfp278v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by De Smet, E.
Right arrow Articles by Quérin, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Smet, E.
Right arrow Articles by Quérin, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy

Eric De Smet, Jean-Philippe Rioux, Hélène Ammann, Clément Déziel and Serge Quérin

Nephrology and Medical Biology Divisions, Hôpital du Sacré-Coeur and Université de Montréal, Montreal, QC, Canada

Correspondence and offprint requests to: Serge Quérin; E-mail: serge.querin{at}umontreal.ca



  Abstract

Some cases of nephrotic syndrome in focal and segmental glomerulosclerosis (FSGS) are associated with a circulating factor, the FSGS permeability factor (FSPF). Galactose has a high affinity for FSPF, and experimental data suggest that it could reduce its activity. We describe the case of a 48-year-old male with a nephrotic syndrome found to be resistant to corticosteroids, immunosuppression and plasmaphaeresis. The patient was given oral galactose as a last resort treatment, which was followed by a remission of his nephrotic syndrome that correlated with a reduction of FSPF activity. This case is the first report of a long-standing remission of an FSPF-associated nephrotic syndrome on oral galactose therapy.

Keywords: focal segmental; galactose; glomerulosclerosis; nephrotic syndrome; permeability factor

Received for publication: 26. 4.09
Accepted in revised form: 19. 5.09


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.